MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3
To identify microRNAs (miRNAs) regulating Notch3 expression in association with paclitaxel resistance, candidate miRNAs targeting Notch3 were predicted using TargetScan. We found that miR-136 directly targets Notch3, and miR-136 was significantly downregulated in OSC tissues relative to normal control tissues, and low expression of miR-136 correlated with poor overall in ovarian cancer patients. Artificial miR-136 overexpression significantly reduced cell viability, proliferation, Cancer stem cell (CSC) spheroid formation, and angiogenesis, and increased apoptosis in paclitaxel-resistant SKpac cells compared with the effects of paclitaxel alone. miR-136 overexpression downregulated cell survival- (survivin, DNA-PK, pS6, S6) and cell cycle- (Cyclin D1, NF-κB) related proteins, and anti-apoptotic proteins (BCL2, and BCL-XL), and upregulated pro-apoptotic proteins (Bim, Bid, and Bax). Taken together, miR-136 targets the Notch3 oncogene and functions as a tumor suppressor. miR-136 overexpression resensitized paclitaxel-resistant ovarian cancer cells and reduced CSC activities, suggesting a promising new target for the treatment of chemoresistant ovarian cancers..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:386 |
|---|---|
| Enthalten in: |
Cancer letters - 386(2017), Seite 168-178 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeong, Ju-Yeon [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.canlet.2016.11.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1990297986 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1990297986 | ||
| 003 | DE-627 | ||
| 005 | 20230510161654.0 | ||
| 007 | tu | ||
| 008 | 170303s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2016.11.017 |2 doi | |
| 028 | 5 | 2 | |a PQ20170301 |
| 035 | |a (DE-627)OLC1990297986 | ||
| 035 | |a (DE-599)GBVOLC1990297986 | ||
| 035 | |a (PRQ)c1262-c1331850255b49230a6c0c1eba1d027f769750ca0d8ffa37a6f8d18097646adf0 | ||
| 035 | |a (KEY)0019274020170000386000000168microrna136inhibitscancerstemcellactivityandenhanc | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q DNB |
| 084 | |a BIODIV |2 fid | ||
| 100 | 1 | |a Jeong, Ju-Yeon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3 |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a To identify microRNAs (miRNAs) regulating Notch3 expression in association with paclitaxel resistance, candidate miRNAs targeting Notch3 were predicted using TargetScan. We found that miR-136 directly targets Notch3, and miR-136 was significantly downregulated in OSC tissues relative to normal control tissues, and low expression of miR-136 correlated with poor overall in ovarian cancer patients. Artificial miR-136 overexpression significantly reduced cell viability, proliferation, Cancer stem cell (CSC) spheroid formation, and angiogenesis, and increased apoptosis in paclitaxel-resistant SKpac cells compared with the effects of paclitaxel alone. miR-136 overexpression downregulated cell survival- (survivin, DNA-PK, pS6, S6) and cell cycle- (Cyclin D1, NF-κB) related proteins, and anti-apoptotic proteins (BCL2, and BCL-XL), and upregulated pro-apoptotic proteins (Bim, Bid, and Bax). Taken together, miR-136 targets the Notch3 oncogene and functions as a tumor suppressor. miR-136 overexpression resensitized paclitaxel-resistant ovarian cancer cells and reduced CSC activities, suggesting a promising new target for the treatment of chemoresistant ovarian cancers. | ||
| 650 | 4 | |a Ovarian cancer | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Pathology | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Cell cycle | |
| 650 | 4 | |a Deoxyribonucleic acid--DNA | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Medical prognosis | |
| 650 | 4 | |a Cell growth | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a Conflicts of interest | |
| 650 | 4 | |a Stem cells | |
| 650 | 4 | |a Cancer therapies | |
| 650 | 4 | |a Binding sites | |
| 650 | 4 | |a Proteins | |
| 700 | 1 | |a Kang, Haeyoun |4 oth | |
| 700 | 1 | |a Kim, Tae Hoen |4 oth | |
| 700 | 1 | |a Kim, Gwangil |4 oth | |
| 700 | 1 | |a Heo, Jin-Hyung |4 oth | |
| 700 | 1 | |a Kwon, Ah-Young |4 oth | |
| 700 | 1 | |a Kim, Sewha |4 oth | |
| 700 | 1 | |a Jung, Sang-geun |4 oth | |
| 700 | 1 | |a An, Hee-Jung |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d Amsterdam : Elsevier, 1975 |g 386(2017), Seite 168-178 |w (DE-627)166458880 |w (DE-600)195674-7 |w (DE-576)01481272X |x 0304-3835 |7 nnns |
| 773 | 1 | 8 | |g volume:386 |g year:2017 |g pages:168-178 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.canlet.2016.11.017 |3 Volltext |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1852982433 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 386 |j 2017 |h 168-178 | ||